Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries has announced final results from the global Phase II trial of glatiramer acetate 40mg, for the treatment of amyotrophic lateral sclerosis.
Subscribe to our email newsletter
Results show that GA 40mg was safe and well-tolerated in ALS patients, however, the study’s primary and secondary endpoints were not met. The study was designed to assess the safety, tolerability and efficacy of glatiramer acetate (GA) 40mg, given once daily as a subcutaneous injection, in reducing disease-related functional deterioration in amyotrophic lateral sclerosis (AML) patients.
Vincent Meininger, principal investigator of the study, said: “Despite our hopes and desires, similar to other drug candidates for the treatment of ALS, GA 40 mg did not prove beneficial for ALS patients but was shown to be safe and well tolerated.”